Metropolitan Life Insurance CO Athira Pharma, Inc. Transaction History

Metropolitan Life Insurance CO

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$2.74 - $13.43 $7,598 - $37,241	-2,773 Closed	0 $0
Q1 2022 Jun 20, 2023	BUY	$8.96 - $13.51 $24,846 - $37,463	2,773 New	2,773 $37,000
Q1 2022 Mar 30, 2023	SELL	$8.96 - $13.51 $67,441 - $101,689	-7,527 Reduced 73.08%	2,773 $37,000
Q1 2022 May 12, 2022	SELL	$8.96 - $13.51 $67,441 - $101,689	-7,527 Reduced 73.08%	2,773 $37,000
Q4 2021 Jun 21, 2023	BUY	$9.17 - $16.39 $94,451 - $168,817	10,300 New	10,300 $134,000
Q4 2021 Mar 30, 2023	BUY	$9.17 - $16.39 $28,344 - $50,661	3,091 Added 42.88%	10,300 $134,000
Q4 2021 Feb 15, 2022	BUY	$9.17 - $16.39 $28,344 - $50,661	3,091 Added 42.88%	10,300 $134,000
Q3 2021 Jun 21, 2023	BUY	$9.15 - $11.09 $65,962 - $79,947	7,209 New	7,209 $67,000
Q3 2021 Mar 30, 2023	SELL	$9.15 - $11.09 $41,577 - $50,392	-4,544 Reduced 38.66%	7,209 $67,000
Q3 2021 Nov 15, 2021	SELL	$9.15 - $11.09 $41,577 - $50,392	-4,544 Reduced 38.66%	7,209 $68,000
Q2 2021 Jun 21, 2023	BUY	$10.24 - $20.87 $120,350 - $245,285	11,753 New	11,753 $120,000
Q2 2021 Mar 30, 2023	BUY	$10.24 - $20.87 $75,151 - $153,164	7,339 Added 166.27%	11,753 $120,000
Q2 2021 Aug 16, 2021	BUY	$10.24 - $20.87 $120,350 - $245,285	11,753 New	11,753 $120,000
Q1 2021 May 14, 2021	SELL	$16.9 - $29.77 $74,596 - $131,404	-4,414 Closed	0 $0
Q4 2020 Jun 22, 2023	BUY	$16.48 - $34.3 $72,742 - $151,400	4,414 New	4,414 $151,000
Q4 2020 Mar 30, 2023	BUY	$16.48 - $34.3 $72,742 - $151,400	4,414 New	4,414 $151,000
Q4 2020 Feb 16, 2021	BUY	$16.48 - $34.3 $72,742 - $151,400	4,414 New	4,414 $151,000

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $24.2M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.